A Phase 3, Multicenter, Randomized, Double-Masked, Vehicle-Controlled Clinical Study to Assess the Efficacy and Safety of 5% Tavilermide Ophthalmic Solution for the Treatment of Dry Eye
Latest Information Update: 13 Jun 2024
At a glance
- Drugs Tavilermide (Primary)
- Indications Dry eyes
- Focus Registrational; Therapeutic Use
- Sponsors Mimetogen Pharmaceuticals
Most Recent Events
- 06 Jun 2024 Status changed from active, no longer recruiting to completed.
- 14 Dec 2023 Status changed from recruiting to active, no longer recruiting.
- 01 Aug 2023 Planned End Date changed from 1 Mar 2024 to 1 May 2024.